康寧傑瑞(09966.HK)逆漲11% 兩新藥臨床試驗初步結果獲美學會肯定
康寧傑瑞製藥-B(09966.HK)公布旗下兩新藥KN026及KN046臨床試驗初步結果已獲即將召開2020年美國臨床腫瘤學會(ASCO)年會接受以海報形式呈列。該股今天逆市突破近期小雙頂位,最高見19.42元,暫受制2月所創上市高位20.65元,現造18.94元,急彈11%,成交額3,184萬元。
康寧傑瑞為一家內地領先臨床階段未獲盈利生物科技公司。股份去年12月中旬才以每股10.2元來港上市。公司通告指,目前KN026正分別在中國及美國進行數項II期及I期臨床試驗,該新藥已在晚期乳腺癌患者中表現出良好初步療效。至於KN046目前正在進行對NSCLC、三陰乳腺癌(TNBC)、食管鱗狀細胞癌(ESCC)及胰腺癌的多項II期臨床試驗。該等臨床試驗結果將於各種場合發布,該藥品有望成為第二代免疫腫瘤治療藥物的基石藥物之一。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.